Vectibix(R) Now Available For The Treatment Of Advanced Colorectal Cancer In Belgium

Amgen Belgium announces the availability of Vectibix® (panitumumab), the first fully human anti-EGFR monoclonal antibody indicated as monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) with non-mutated (wild-type) KRASgene after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy protocols.